Hamlet Pharma

Hamlet BioPharma is pleased to announce the continuation of the digital event series this autumn. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during the Q&A sessions that will follow each presentation. Please visit our web page to join the digital events: https://hamletbiopharma.com/series-of-digital-events-2024/

The digital event are scheduled for:

• September 18th, 2024, 12:00 CET
• October 23rd, 2024, 12:00 CET
• December 11th, 2024, 12:00 CET

Additionally, please note the following dates for quarterly reports:

• August 28th, 2024: Year-End Report (Q4) 2023/2024
• October 31st, 2024: Annual Report 2023/2024
• November 15th, 2024: Quarterly Report (Q1) 2024/2025

We would also like to inform you that the Annual General Meeting 2023/2024 is scheduled for November 21st, 2024, to be held in Malmö, Sweden.

To receive information from the company, please subscribe at  https://hamletbiopharma.com/subscribe/).

For more information please contact:

Martin Erixon, CEO, Hamlet BioPharma AB, +46 733 00 43 77

martin.erixon@hamletpharma.com

Catharina Svanborg, Chairman of the board, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com